Negative in Ames and in vivo rat micronucleus; in vitro chromosome aberration negative for structural, positive for numerical (polyploidy)
“The outcome of the bacterial Ames test and the micronucleus test was negative. In the in vitro mammalian chromosome aberration test in human peripheral blood lymphocytes, upadacitinib was found negative for induction of structural chromosome aberrations but positive for induction of numerical chromosome aberration.”
Not carcinogenic in 2-year rat (~4-10x clinical AUC) or 26-week Tg(HRAS) transgenic mouse studies
“Upadacitinib, at exposures (based on AUC) approximately 4 and 10 times the clinical dose of 15 mg in male and female Sprague-Dawley rats, respectively, was not carcinogenic in a 2 year carcinogenicity study in Sprague-Dawley rats. Upadacitinib was not carcinogenic in a 26 week carcinogenicity study in CByB6F1-Tg(HRAS)2Jic transgenic mice.”
Rat fertility (post-implantation loss), rat and rabbit EFD (skeletal malformations); no adverse PPND findings
“Adverse effects attributed to UPA were observed in the rat fertility (increased postimplantation loss and reduced live fetuses per litter), rat EFD (skeletal malformations), and rabbit EFD (skeletal malformations, postimplantation loss, decreased fetal body weights) studies. No adverse findings were noted in the PPND study.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Safety pharmacology
hERG IC50 39.5 µg/mL, several hundred-fold above clinical plasma concentrations
“The IC50 for hERG blockade was 39.5 μg/mL, which is several hundred-fold above clinical plasma concentrations.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative